Introduction {#S1}
============

Nodal marginal zone lymphoma, extra-nodal marginal zone lymphoma of MALT, splenic marginal zone lymphoma, and lymphoplasmacytic lymphoma([@R1], [@R2]) are indolent lymphomas accounting for approximately 10% of all non-Hodgkin lymphomas([@R1]). MALT lymphoma is the most frequent subtype, representing 50% to 70% of marginal zone lymphomas, followed by splenic and nodal marginal zone lymphomas, which represent 20% and 10% of cases, respectively. Lymphoplasmacytic lymphoma, accounting for 1% of non-Hodgkin lymphomas, is a heterogeneous entity with cytological spectrum ranging from small B cell lymphocytes, plasmacytoid lymphocytes to mature plasma cells and is characterized by frequent involvement of lymph nodes and bone marrow([@R3]). MALT lymphomas harbor several characteristic chromosomal abnormalities, including trisomies 3 and 18, deletion of 6q and a number of translocations, including t(11;18)(q21;q21) *API2-MALT1*, t(14;18)(q32;q21) *IGH-MALT1*, t(1;14)(p22;q32) *IGH-BCL10*, t(3;14)(q27;q32) and t(3;14)(p14.1;q32) *IGH-FOXP1*([@R4]--[@R12]). The translocations are mutually exclusive, but often they are present in conjunction with other genomic abnormalities, with the exception of the t(11;18) *API2-MALT1*, which usually is the sole chromosomal abnormality([@R13]). Interestingly, at least four of these translocations cause over expression of *MALT1* or *BCL10*, leading to constitutive activation of the nuclear factor kappa B (NF-kB) signaling pathways - a common pathogenesis pathway in MALT lymphomas([@R14]--[@R16]). However, depending on the anatomic location, 25--75% of MALT lymphomas do not harbor any of these chromosomal translocations.

Knowledge surrounding the genetic events characterizing splenic, nodal and lymphoplasmacytic lymphoma is more limited. Splenic marginal zone lymphoma is mainly characterized by the presence of recurrent deletions on 7q32--q35([@R11], [@R17]--[@R19]). Whole or partial gains of chromosomes 3 and 12 and losses of 17p have also been identified in this entity([@R18], [@R20]). In nodal marginal zone lymphoma some initial studies have highlighted the presence of whole or partial gains on chromosomes 3, 6p, 12 and 18([@R10]), but no unique abnormalities have been identified. Finally, few recurrent abnormalities (6q deletion, 6p gain and whole or partial gains on chromosomes 3, 4 and 18) have been identified in lymphoplasmacytic lymphoma, mainly in cases associated with Waldenström's Macroglobulinemia([@R21]--[@R23]).

Consequently, there is a limited knowledge regarding the pathogenesis of these diseases and what are the genetic events contributing to malignant transformation. The aim of this study was to perform a comprehensive high-resolution genomic analysis in a large series of marginal zone/lymphoplasmacytic lymphoma to better characterize the genetic basis of the different entities and identify molecular mechanisms involved in the pathogenesis of these indolent B-cell non-Hodgkin lymphomas.

Materials and Methods {#S2}
=====================

Patient samples {#S3}
---------------

One hundred fourteen patients were included in this study: 46 MALT lymphomas (22 pulmonary, 11 salivary glands, 7 lacrimal glands and 6 gastrointestinal), 35 splenic marginal zone lymphomas, 20 nodal marginal zone lymphomas and 13 non-Waldenström's Macroglobulinemia lymphoplasmacytic lymphomas. All cases were reviewed prior to study on paraffin sections with immunohistochemistry. Sections of each frozen tissue used for study were also reviewed by histological examination and immunohistochemistry before was submitted for the study. All cases were diagnosed according to the criteria established by the 2008 World Health Organization Classification of Lymphoid Neoplasms([@R24]).

The Waldenström's Macroglobulinemia cases were excluded from this study. The cases fulfilling the criteria for Waldenström's Macroglobulinemia according to the 2008 World Health Organization classification and International Workshop On Waldenström's Macroglobulinemia([@R25], [@R26]) were published in a previous study([@R21]). The diagnostic criteria for Waldenström's Macroglobulinemia are the presence of i) a lymphoplasmacytic lymphoma morphology as described in the 2008 World Health Organization classification, ii) bone marrow involvement, iii) any level of IgM paraprotein. The cases included in this study either lacked evidence of bone marrow involvement or IgM paraprotein. Of the 13 cases of lymphoplasmacytic lymphomas analyzed in this study, 6 cases lacked a monoclonal gammopathy at presentation. Remaining cases either had IgG or IgA gammopathy or IgM gammopathy without evidence of BM involvement. The lymphoplasmacytic lymphomas cases were composed of a mixture of small lymphocytes, small lymphoplasmacytoid cells, and occasional plasma cells. Architecturally the infiltrate was diffuse with a predominantly paracortical and medullary pattern often sparing the medullary sinuses. In contrast, the nodal marginal zone lymphoma cases contained intermediate sized cells with abundant pale cytoplasm (so-called monocytoid cytology). They lacked lymphoplasmacytoid cells and plasma cell differentiation was minimal or absent. The cases that cannot be clearly classified into these two categories were not included in the study. Finally, the so-called variants such as splenic lymphoma villous lymphocytes, or splenic B-cell lymphoma unclassified were not studied.

Eight of the 46 MALT lymphomas were previously shown to have t(11;18)(q21;q21) *API2-MALT1* by FISH analysis([@R27]). Tumor purity was estimated by percent of CD20 positive cells in the tumors with a median of 70% (range 20--100%). Tissues analyzed of each case are shown in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}. Biospecimens were collected after informed consent was obtained in accordance with the Declaration of Helsinki in each of the participating centers and the study was conducted following Institutional Review Board approval in all the centers.

Array-based comparative genomic hybridization {#S4}
---------------------------------------------

Genomic DNA was obtained from snap-frozen tissue using standard phenol-chloroform extraction methods. High-resolution array-based comparative genomic hybridization was performed with the Human Genome 244A microarray (Agilent Technologies; Palo Alto, CA). The digestion, labeling and hybridization steps were done as previously described with minor modifications([@R21]). Briefly, 1.2 μg of tumor and reference DNAs were separately digested with Bovine DNaseI (Ambion; Austin, TX) for 12 minutes at room temperature. Random primers and exo-Klenow fragment (Invitrogen; Carlsbad, CA) were used to differentially label tumor (Cy5) and reference (Cy3) genomic DNA samples (GE Healthcare; Piscataway, NJ). Labeled genomic reactions were cleaned-up by purification columns (Invitrogen) and hybridized at 65° C for 40 hours. Microarrays were scanned in a DNA Microarray Scanner (Agilent Technologies). Feature extraction was performed with Feature extraction Software, version 9.5 (Agilent Technologies). Log2 ratio data was imported and analyzed using DNA Analytics software version 4.0.85 (Agilent Technologies).

Copy-number abnormalities were calculated using aberration detection module 1 algorithm([@R28]) with a threshold of 7.5. A 2 probe, 0.25_log2 filters were used in the aberration detection, obtaining an average genomic resolution of 17 Kb. Copy number variations were identified and excluded from the analysis as previously described([@R21]).

Unsupervised hierarchical clustering and Pearson correlation were performed using Genespring software. An in house algorithm was used to represent the penetrance plots.

FISH {#S5}
----

FISH DNA probes to validate copy-number changes affecting *TNFAIP3* was selected for a fosmid clone using the UCSC genome browser. The normal cutoff for scoring FISH probes was determined using normal controls and was of 10%. One hundred cells from formalin-fixed paraffin embedded tissues were scored in each case. The specificity of each probe at chromosome and gene level was confirmed by hybridization to normal metaphase preparations and by gene specific PCR, respectively. A list of probes used and chromosomal localization is provided in [Supplementary Table S2](#SD3){ref-type="supplementary-material"}.

DNA sequencing {#S6}
--------------

Genome sequencing was performed on the *TNFAIP3* coding exons and adjacent intron-exon junctions in all lymphoplasmacytic lymphomas and in 20 MALT patients. All the coding regions were amplified using 10 ng of genomic DNA in 25 μl reactions. The specific primers used in this study are listed in [Supplementary Table S3](#SD4){ref-type="supplementary-material"}. Capillary electrophoresis was performed on an ABI3730 sequencer (Applied Biosystems; Foster City, CA). DNA sequences were analyzed using Sequencher V4.5.

Statistic analysis {#S7}
------------------

Genomic complexity, defined as the total size across all detected gains, and likewise, across all detected losses, was evaluated both as a continuous variable and as a categorical variable. ANOVA and two-tailed t-test were used to test for associations. Statistical significance was considered when *p* \< 0.05.

Results {#S8}
=======

Overview of copy number abnormalities {#S9}
-------------------------------------

We performed array-based comparative genomic hybridization in 13 non-Waldenström's Macroglobulinemia lymphoplasmacytic lymphomas and 101 marginal zone lymphoma patients, including 46 MALT lymphomas, 35 splenic and 20 nodal marginal zone lymphomas. A total of 90% (103 of 114) cases had copy-number abnormalities, ranging from 85% of nodal marginal zone lymphomas to 92% of lymphoplasmacytic lymphomas. The number of copy-number abnormalities was used as a measurement of the genomic complexity of each patient sample ([Supplementary Table S4](#SD5){ref-type="supplementary-material"}). Overall, 719 copy-number abnormalities were found, comprising 427 losses and 292 gains. Homozygous deletions and multiple copy gains were rare (17 biallelic deletions and 23 2--3 extra copy gains, respectively). Conversely, no gene amplifications (\>3 extra copies) were found. Lymphoplasmacytic lymphomas was the entity with the largest number of abnormalities (median of 7 copy-number abnormalities per sample; range: 0 -- 44), followed by MALT lymphomas without t(11;18)(q21;q21) (4; 0 -- 18), nodal (3.5; 0 -- 35), splenic (3; 0 -- 66) and finally MALT lymphomas with t(11;18)(q21;21) (1; 0 -- 4) ([Table 1](#T1){ref-type="table"}). A graphic representation of all abnormalities detected per entity, type (gains and losses), prevalence and chromosome location is shown in [Figure 1](#F1){ref-type="fig"}. The complete set of abnormalities is described in [Supplementary Table S5](#SD6){ref-type="supplementary-material"}.

It is remarkable that, even using this high-resolution microarray platform, MALT lymphomas with the t(11;18)(q21;q21) show a very stable karyotype, without any recurrent abnormality with the exception of losses flanking *MALT1* and *BIRC3*, which are a cytogenetic consequence of unbalanced t(11;18)(q21;21) translocations ([Figure 2](#F2){ref-type="fig"} and [Tables S4](#SD5){ref-type="supplementary-material"} -- [S5](#SD6){ref-type="supplementary-material"}). For this reason, unless specified, MALT lymphoma patients with t(11;18)(q21;q21) were excluded from the remaining analyses of this study.

Common abnormalities to all entities {#S10}
------------------------------------

Eight abnormalities were recurrently found in all entities: whole or partial gains of chromosomes 3, 12 and 18, gain of 1q23--q25, and deletions of cytobands 1p21--p22, 1q42, 6q23.3--q24.1 and 13q14 ([Figures 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Unsupervised hierarchical analysis shows clusters based on the main abnormalities but without obtaining a good differentiation between lymphoma entities ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Whole or partial gains of chromosomes 3 and 18 were the most common abnormalities seen in MALT lymphomas (37% and 40%, respectively) and one of the most frequent abnormalities in the remaining diseases, ranging from 15% (chromosome 3) and 23% (chromosome 18) in lymphoplasmacytic lymphomas to 15% of each in nodal marginal zone lymphomas ([Table 2](#T2){ref-type="table"}). The minimal gained regions were located at 3q23--q24 (4.3 Mb) and 18q21.2--q21.33 (9.3 Mb), the last one including *MALT1* but not *BCL2*. The concomitant gain of chromosomes 3 and 18 was observed in MALT lymphomas (*p* = 0.002) and lymphoplasmacytic lymphoma (*p* = 0.002) but not in nodal or splenic marginal zone lymphomas (*p* \> 0.05).

The prevalence of whole or partial gain of chromosome 12 ranges from 5% in MALT lymphomas to 25% in nodal marginal zone lymphomas and a minimal gain region of 29 megabases was refined on 12q13.13--q21.31 ([Table 2](#T2){ref-type="table"}). Deletion of 6q was the most common abnormality in lymphoplasmacytic lymphoma (46%). This deletion was also present in a substantial number of MALT lymphomas (21%) and less frequently in splenic and nodal marginal zone lymphomas ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Lymphoplasmacytic lymphoma was primarily characterized by loss of the entire 6q arm. In a subset of lymphoplasmacytic lymphomas, focal deletions were identified and four minimal deleted regions were defined on 6q21, 6q22.31, 6q23.3--q24.1 and 6q24.2, the third of them overlapping with the minimal deleted region identified in MALT lymphomas. Biallelic and focal monoallelic deletions on 6q23.3--q24.1 identified *TNFAIP3* as the sole gene inside the common minimal deleted region in all the entities ([Supplementary Figure 2a](#SD1){ref-type="supplementary-material"}), subsequently confirmed by interphase FISH ([Supplementary Figure 2b](#SD1){ref-type="supplementary-material"}). *TNFAIP3* biallelic deletions were identified in lymphoplasmacytic lymphomas and all marginal zone lymphoma entities except splenic marginal zone lymphomas ([Supplementary Figure 2c](#SD1){ref-type="supplementary-material"}). In MALT lymphomas, biallelic deletions were identified in lacrimal glands/ocular adnexa (2 of 6 cases) and salivary glands (2 of 12), and focal monoallelic deletions were found in salivary glands (1 of 12), stomach (1 of 2), bowel (1 of 3) and lung (1 of 15)([Supplementary Figure 2d](#SD1){ref-type="supplementary-material"}). All the coding regions of *TNFAIP3* were sequenced in 20 MALT and 13 lymphoplasmacytic lymphoma cases, but no mutations were identified.

Chromosome 13 deletions were observed in all entities, but the affected region varies between entities. Nodal marginal zone and MALT lymphomas were characterized by whole chromosome 13 deletions, as is observed in myeloma, whereas focal deletions on 13q14.3, including the microRNAs *MIR15A* and *MIR16-1,* were identified in lymphoplasmacytic and splenic marginal zone lymphomas ([Figure 1](#F1){ref-type="fig"}). This focal region is equivalent to the most common copy-number abnormality in chronic lymphocytic leukemia.

Recurrent abnormalities in lymphoma subsets {#S11}
-------------------------------------------

Several chromosomal regions were involved in recurrent imbalances in more than one lymphoma entity but were absent in others ([Figure 3](#F3){ref-type="fig"}). Seventeen minimal deleted and nine minimal gain regions were defined based on the presence in at least one entity with a frequency of 10% or higher ([Table 2](#T2){ref-type="table"}).

Deletion of 7q32.1--q33 was the most common abnormality in splenic marginal zone lymphoma (26%), but it was also identified in lymphoplasmacytic lymphomas (8%) and MALT lymphomas (5%), but not in nodal marginal zone lymphomas ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). A 14.8 megabases minimal deleted region including 81 genes and 10 microRNAs, was delineated ([Supplementary Table S6](#SD7){ref-type="supplementary-material"}). In all cases, the abnormality affected only one allele. The number of molecular alterations in splenic marginal zone lymphoma suggests a significant degree of molecular heterogeneity. Splenic marginal zone lymphomas with deletion of 7q32.1--q33 were characterized for having a slight, but not statistically significant, increase in the number of copy-number abnormalities per karyotype (median of 6 copy-number abnormalities per karyotype) when compared to patients without deletion of 7q (median of 3 abnormalities). Conversely, several recurrent abnormalities were only identified in the group without deletion of 7q such as deletion of 13q14.3 (16% of patients without deletion), whole or partial gain of chromosome 18 (24%) and partial gains of Xp (12%) ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}).

Deletion of 17p13.3-p12, containing *TP53*, was identified in lymphoplasmacytic (15%) and splenic marginal zone lymphomas (14%) but not in MALT or nodal marginal zone lymphomas. This abnormality was associated with a significantly more complex karyotype in splenic marginal zone lymphomas cases (median of 25 versus 3 copy-number abnormalities in cases without 17p deletion; p \< 0.0001). The presence of deletion of 7q was not correlated with deletion of 17p in splenic marginal zone lymphoma cases.

Recurrent deletions on 11q21--q22 were identified in all lymphoma entities, with the exception of MALT lymphomas, ranging from 15% in nodal to 11% in splenic marginal zone lymphomas ([Table 2](#T2){ref-type="table"}). A 12.77 megabases minimal deleted region was delineated, including *ATM* and 45 genes additional genes.

Focal deletions on 9p21.3 including *CDKN2A* were identified in lymphoplasmacytic, splenic and nodal marginal zone lymphoma patients but not in any MALT lymphomas. Recurrent gains on 1q23.3--q25.3 were identified in lymphoplasmacytic and nodal marginal zone lymphoma. Deletion of 1p21.2--p22.1 was mainly observed in nodal marginal zone lymphoma (15%) but also in low frequency of splenic and lymphoplasmacytic lymphoma cases. Whole or partial gains on 6p were common to all entities with the exception of splenic marginal zone lymphoma.

Finally, some abnormalities were only recurrent in one lymphoma entity. Gain of chromosome 9 was only found in lymphoplasmacytic lymphomas. Deletion of 15q25.3--q26.2 was the second most common abnormality found in nodal marginal zone lymphoma (15%) but was absent in the remaining entities, with the exception of one MALT lymphoma case. ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

Copy-number abnormalities affecting regulators of the NF-kB pathway {#S12}
-------------------------------------------------------------------

In addition to 17% of cases with t(11;18); extra copies of *MALT1* (18q21) and/or focal gains of *REL* (2p15--p16) and/or monoallelic/biallelic deletions affecting *TNFAIP3* (6q23) were identified in an additional 46% of MALT lymphomas, totaling 63% of MALT lymphoma cases with abnormalities affecting regulatory genes from the NF-kB signaling pathway ([Figure 4a](#F4){ref-type="fig"}). Depending on the anatomic site, the prevalence of NF-kB abnormalities varies from 50% in lacrimal glands to 75% in salivary glands ([Figure 4b](#F4){ref-type="fig"}). These abnormalities were identified alone or in combination, but all of them were mutually exclusive with the t(11;18)(q21;21).

In lymphoplasmacytic lymphomas, no translocations leading to the activation of the NF-kB signaling pathway have been described. However, deletions of *TNFAIP3, TRAF3*, and gains of *MALT1* and *REL* alone or in combination were identified in 61.5% of cases (8 of 13 patients) ([Figure 4a](#F4){ref-type="fig"}). Abnormalities affecting the major regulatory genes of the NF-kB signaling pathways were identified in a significantly lower frequency in nodal (30%) and splenic marginal zone lymphomas (31%).

Discussion {#S13}
==========

In this study we performed a comprehensive, high-resolution, copy-number analysis of non-Hodgkin lymphomas including MALT, nodal and splenic marginal zone lymphomas, and the related entity lymphoplasmacytic lymphoma. The analysis of the genomic complexity based on the number and size of copy-number abnormalities shows a range from a very stable karyotype in MALT lymphomas harboring the t(11;18) *API2-MALT1* to more complex karyotypes such as those seen in lymphoplasmacytic lymphoma. However, overall this subset of lymphomas demonstrates low complexity compared with that observed in more aggressive B-cell diseases([@R29]--[@R32]). The low karyotypic complexity observed in MALT lymphoma cases with the t(11;18) *API2-MALT1* is remarkable. Previous studies using lower resolution approaches have proposed that the classical translocations in MALT lymphomas are present in combination with other genetic abnormalities, with the exception of the t(11;18) *API2-MALT1*, which has been the sole abnormality([@R13]) associated with a very stable karyotype([@R33]). In this study we identified a median of one extra abnormality per karyotype harboring the t(11;18) *API2-MALT1*, but we did not identify any recurrent abnormality other than focal copy-number abnormalities surrounding *API2* and *MALT1*, which are a consequence of unbalanced translocations. Thus, our data confirm the presence of an extremely conserved karyotype in MALT lymphomas with t(11;18) *API2-MALT1*, even given an analysis of the genome with an average resolution of 15 Kb. This finding confirms the existence of a subgroup of cases with a very stable karyotype that are caused by either a unique or very few genetic abnormalities.

At the level of cell differentiation these tumors are very similar (memory B-cell phenotype, with a tendency to plasmacytic differentiation), but also showing distinct clinical features. A comparative analysis across entities exposes a similar scenario at the genomic level, with the presence of a common group of copy-number abnormalities shared by several, or all of the entities with few disease-specific abnormalities. In fact, the genomic similarities are not restricted to the analyzed lymphoma entities but are also common to a larger group of low-grade B-cell malignancies. Indeed, lymphoplasmacytic and splenic marginal zone lymphomas are affected by the most common copy-number abnormalities observed in chronic lymphocytic leukemia, such as deletions of 6q, 11q21--q22, 13q14.3, 17p13 and gains of chromosome 12([@R34]).

Even though no distinctive disease-specific copy-number abnormalities have been identified across the analyzed lymphoma entities, the overall genomic profiles may help us to better differentiate between these entities. Although deletion of 6q23--q24 and partial gain of chromosomes 3 and 18, observed alone or in combination, are present in almost 50% of patients across all entities, these abnormalities are more commonly observed in MALT lymphomas and lymphoplasmacytic lymphoma than in splenic or nodal marginal zone lymphoma. Deletion of 11q21--q22 was observed in lymphoplasmacytic lymphoma, splenic and nodal marginal zone lymphoma, but not in MALT lymphomas. Focal deletion of 13q14.3 including *MIRN15A* and *MIRN16-1* was only found in lymphoplasmacytic and splenic marginal zone lymphoma. Deletion of 17p (including *TP53*) was observed in lymphoplasmacytic lymphoma and splenic, but not in nodal marginal zone or MALT lymphomas. Deletion 7q32.1--q33, previously described in splenic marginal zone lymphoma, was also found at low prevalence in MALT lymphomas and lymphoplasmacytic lymphoma, but not in nodal marginal zone lymphoma. These abnormalities, if validated in future studies, will not only help to elucidate pathogenesis of these lymphoma entities, but may be used for diagnosis confirmation.

We have confirmed previous findings of the importance of the NF-kB pathway in the pathogenesis of these lymphomas. In MALT lymphomas, at least four translocations lead to the overexpression of *MALT1* or *BCL10*, thus unifying all under a common pathogenesis pathway, which results in the constitutive activation of the NF-kB([@R14]--[@R16]). Despite the characterization of several translocations leading to the constitutive activation of the NF-kB signaling pathway, there is also a significant group of MALT lymphoma cases without any identified translocation. Remarkably, 55% of cases without translocations are also characterized by abnormalities affecting regulators of the NF-kB pathway, such as 1--3 copy gains of the positive regulators *MALT1* (18q21) and *REL* (2p15--p16) and mono/biallelic deletions of the negative regulator *TNFAIP3* (6q23--q24). A previous study showed recurrent gains of *TRAF2* in MALT([@R33]), but we did not find abnormalities affecting this gene in our cohort.

*TNFAIP3*/A20 gene is a negative regulator of the NF-KB pathway by controlling *RIP*, *TRAF6* and *NEMO*([@R35], [@R36]) and its inactivation contributes to lymphomagenesis by promoting constitutive activation of the NF-κB and enhanced cell survival. Consistent with the tumor-suppressive function of *TNFAIP3*, reintroduction of the wild-type A20 into A20-deficient lymphoma cell lines suppressed cell growth, promoted apoptosis and downregulated NF-κB activity([@R37]--[@R40]). We and others have recently demonstrated the presence of *TNFAIP3* deletions and mutations in a broad set of B-cell diseases([@R12], [@R21], [@R37]--[@R42]). In this study we confirmed the presence of homozygous deletions in MALT lymphomas, nodal marginal zone and lymphoplasmacytic lymphoma as well as focal monoallelic deletions in all analyzed lymphoma entities. Contrary to other recent studies we did not find mutations in *TNFAIP3* leading to the inactivation of the second allele([@R21], [@R37], [@R38], [@R43]).

Interestingly, the protease MALT1 interacts with A20, by cleaving and inactivating it, thus enhancing NF-κB signaling([@R44]). Thus, alterations affecting these two regulators may act synergistically in the activation of NF-kB. As the list of cytogenetic alterations involving other NF-kB pathway members currently implicated in MALT lymphoma grows, the unifying theory([@R14]--[@R16]) receives strong support and suggests that there is also a synergistic interplay between several abnormalities affecting the NF-kB pathway other than the translocations found in MALT lymphoma. It might be hypothesized that these additional abnormalities, together with the chronic immunological stimulations, leads to biological consequences similar to those caused by the chromosomal translocation associated with MALT lymphoma. These findings provide a rationale for exploring proteasome inhibitor based therapeutic strategies for patients with recurrent or refractory disease.

More intriguing is the role the NF-kB pathway plays in lymphoplasmacytic lymphoma, where no translocations have been identified. Besides copy-number abnormalities affecting *TNFAIP3*, *MALT1* and *REL*, focal deletions and mutations affecting *TRAF3* were identified in this and in previous studies involving other B-cell malignancies([@R21], [@R29], [@R45]). Remarkably, 67% of lymphoplasmacytic lymphoma cases show copy-number abnormalities affecting this pathway, thus highlighting the role of the NF-kB pathway in lymphoplasmacytic lymphoma, whether associated with Waldenström's Macroglobulinemia or not. This does not seem to be the case in nodal or marginal zone lymphoma, where chromosomal abnormalities affecting the NF-kB pathway were identified at a significantly lower prevalence, thereby suggesting that the activation of this pathway does not have the central role observed in MALT lymphomas and lymphoplasmacytic lymphoma.

In conclusion, we performed a comprehensive high-resolution genomic analysis in a large series of marginal zone lymphomas and lymphoplasmacytic lymphomas to better dissect the genetic basis of these entities. Although the entities share a common set of genomic abnormalities they are also characterized by the presence of genes and cellular pathways differentially affected. Elucidation of the genetic alterations contributing to the pathogenesis of the analyzed non-Hodgkin lymphoma subtypes may guide design of specific therapeutic approaches.
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======================

This work was supported by a University of Iowa/Mayo ClinicLymphoma SPORE grant from *the National Cancer Institute/National Institutes of Health (NCI/NIH; CA097274).*

**Authorship contributors and Disclosure of Conflicts of Interest**

E.B., A.D., R.F. design the study; E.B., W.C., J.J.K., G.H., M.B. performed the research; A.D., J.M., D.B., I.S.L., T.W. contributed with patient samples; E.B., R.F., I.S.L, J.M.M. wrote the paper; all authors reviewed and gave final approval of the manuscript.

R.F. is a consultant for Genzyme, Medtronic, BMS, Amgen, Otsuka, Celgene, Intellikine and Lilly (all less than \$10,000). R.F. receives research support from Cylene, Onyx and Celgene.

![Overview of the copy-number abnormalities identified in marginal zone and lymphoplasmacytic lymphomas. Chromosomes 1 to Y are represented from left to right. Light gray blocks represent chromosome gains, whereas dark gray blocks represent chromosome losses. The amplitude in each abnormal region represents the frequency of each copy-number abnormality.](nihms345808f1){#F1}

![Copy-number abnormality comparison between MALT lymphomas with and without t(11;18) *API2-MALT1*. Chromosomes 1 to Y are represented from left to right. Light gray blocks represent chromosome gains, whereas dark gray blocks represent chromosome losses. The amplitude in each abnormal region represents the frequency of each copy-number abnormality.](nihms345808f2){#F2}

![Venn diagram summarizing the common and distinct copy-number abnormalities between entities. Abnormalities found in \>10% of at least one entity are shown.](nihms345808f3){#F3}

![**A)** Bar graphic showing the frequency of copy-number abnormality affecting key regulators of the NF-kB signaling pathways per entity. **B)** Bar graphic showing the frequency of copy-number abnormality affecting key regulators of the NF-kB signaling pathways in MALT lymphomas depending on the anatomic site of origin. LG: lacrimal glands; SG: salivary glands; BS: Bowel and stomach.](nihms345808f4){#F4}

###### 

Sumary of number and size of abnormalities per entity.

  Entity                            N    Median number of copy-number abnormalities per case   Mean number of copy-number abnormalities per case   Range
  --------------------------------- ---- ----------------------------------------------------- --------------------------------------------------- -------
  Non-Waldenstrom's                                                                                                                                
  Macroglobulinemia                 13   7                                                     11                                                  3--21
  lymphoplasmacytic lymphoma                                                                                                                       
  Nodal marginal zone lymphomas     20   3.5                                                   6                                                   0--35
  Splenic marginal zone lymphomas   35   3                                                     7                                                   0--66
  MALT lymphomas                    46   3                                                     4                                                   0--18
   MALT without t(11;18)            38   4                                                     5                                                   0--18
   MALT with t(11;18)               8    1                                                     2                                                   0--4

###### 

List of minimal deleted and minimal gained regions identified in \>10% of cases in one or more entities. Copy-number abnormalities present in 10--20% are in light gray boxes, copy-number abnormalities \>20% are in dark gray boxes.

  Event     Cytoband           Start (bp)    Stop (bp)     Size (Mb)   Nodal marginal zone lymphomas ([@R20])   Lymphoplasmacytic lymphomas ([@R13])   Splenic marginal zone lymphomas ([@R35])   MALT lymphomas ([@R38])
  --------- ------------------ ------------- ------------- ----------- ---------------------------------------- -------------------------------------- ------------------------------------------ -------------------------
  CN loss   1p21.2--p22.1      94,131,585    103,829,936   9.7         15                                       7.7                                    5.7                                        2.6
  CN loss   1q42.3             232,809,474   233,657,080   0.85        10                                       7.7                                    14.3                                       2.6
  CN loss   6q21               105,423,847   110,194,804   4.77        10                                       46.1                                   5.7                                        2.6
  CN loss   6q22.31            119,694,067   120,249,386   0.56        10                                       38.5                                   5.7                                        2.6
  CN loss   6q23.3--q24.1      137,982,509   138,292,603   0.31        10                                       46.1                                   11.4                                       21.1
  CN loss   6q24.2             143,040,435   143,616,681   0.58        5                                        30.8                                   8.6                                        10.5
  CN loss   7q32.1--q33        127,287,795   133,367,246   6.08        0                                        7.7                                    26                                         5.2
  CN loss   11q21--q22         97,092,852    109,858,814   12.77       15                                       15.4                                   11.4                                       0
  CN loss   13q14.3            49,485,198    49,917,506    0.43        15                                       15.4                                   11.4                                       2.6
  CN loss   14q12--q13.1       30,878,740    32,266,770    1.39        0                                        15.4                                   0                                          0
  CN loss   15q25.3--q26.2     85,029,553    93,129,421    8.1         15                                       0                                      0                                          2.6
  CN loss   17p13.1            7,149,131     8,106,985     0.96        0                                        23.1                                   14.3                                       0
  CN gain   1q23.3--q25.3      157,659,528   184,755,949   27.1        15                                       7.7                                    2.8                                        0
  CN gain   2p15--p16          58,802,364    61,259,418    2.46        0                                        7.7                                    2.8                                        10.5
  CN gain   3q23--q24          143,871,135   148,165,451   4.29        15                                       23.1                                   11.4                                       36.9
  CN gain   6p22.1--p25.3      1             29,185,959    29.19       10                                       7.7                                    0                                          10.5
  CN gain   8q23.3--q24.22     114,625,817   136,133,311   19.19       0                                        7.7                                    11.4                                       0
  CN gain   9q21.32--q34.3     85,708,336    140,241,876   54.53       0                                        15.4                                   0                                          0
  CN gain   12q13.13--q21.31   51,647,698    80,538,769    28.89       25                                       23.1                                   14.3                                       5.2
  CN gain   18q21.2--q21.33    49,712,041    58,970,878    9.26        15                                       23.1                                   17.1                                       39.5
